We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
Read MoreHide Full Article
Key Takeaways
TPST shares rose after EMA granted orphan drug status to amezalpat for treating liver cancer.
Amezalpat showed superior survival outcomes in combination with RHHBY's standard of care therapy.
Tempest is also advancing TPST-1495 for FAP, with a phase II study expected to begin in late 2025.
Tempest Therapeutics (TPST - Free Report) announced that the European Medicines Agency (EMA) has granted an orphan drug designation (ODD) to its oral PPAR-alpha antagonist, amezalpat (TPST-1120), for the treatment of patients with hepatocellular carcinoma (HCC), the most common type of liver cancer.
Shares of Tempest were up 14.6% yesterday following the announcement of the news.
TPST's Ongoing Development Activities With Amezalpat
Tempest has an agreement with Swiss pharmaceutical giant Roche (RHHBY - Free Report) to evaluate amezalpat in combination with the latter’s standard-of-care combination therapy, Tecentriq (atezolizumab) and Avastin (bevacizumab), for the first-line treatment of unresectable or metastatic HCC.
Besides EMA’s orphan drug tag, amezalpat received the FDA’s ODD and Fast Track designation for treating HCC earlier this year.
All these designations were based on positive data from the phase Ib/II study, which evaluated amezalpat in combination with RHHBY’s standard-of-care combination therapy, Tecentriq and Avastin, for the first-line treatment of unresectable or metastatic HCC.
Data from the phase Ib/II study have shown that amezalpat, in combination with RHHBY’s standard-of-care combination therapy, Tecentriq and Avastin, demonstrated superior outcomes across multiple study endpoints, including overall survival, compared to the standard of care alone.
Year to date, shares of Tempest have plunged 26.8% against the industry’s rise of 10.4%.
Image Source: Zacks Investment Research
TPST Developing Another Candidate TPST-1495
The company is developing TPST-1495, a novel, highly selective and potent EP2-EP4 dual antagonist, for the treatment of familial adenomatous polyposis (FAP).
Tempest has also received a “Study May Proceed” letter from the FDA to begin a phase II study on TPST-1495 for the treatment of FAP. The study is expected to begin later in 2025, with data from the same expected in 2026.
The FDA has also granted an Orphan Drug designation to TPST-1495 for the treatment of patients with FAP.
Tempest is currently exploring strategic options to advance the clinical studies on its pipeline candidates aimed at increasing stockholder value.
In the past 60 days, estimates for Lexicon’s loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents. Year to date, shares of LXRX have lost 2.9%.
LXRX’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%.
In the past 60 days, estimates for Chemomab Therapeutics’ loss per share have narrowed from 70 cents to 60 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 80 cents to 70 cents. Year to date, shares of CMMB have declined 27.9%.
CMMB’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 5.00%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
Key Takeaways
Tempest Therapeutics (TPST - Free Report) announced that the European Medicines Agency (EMA) has granted an orphan drug designation (ODD) to its oral PPAR-alpha antagonist, amezalpat (TPST-1120), for the treatment of patients with hepatocellular carcinoma (HCC), the most common type of liver cancer.
Shares of Tempest were up 14.6% yesterday following the announcement of the news.
TPST's Ongoing Development Activities With Amezalpat
Tempest has an agreement with Swiss pharmaceutical giant Roche (RHHBY - Free Report) to evaluate amezalpat in combination with the latter’s standard-of-care combination therapy, Tecentriq (atezolizumab) and Avastin (bevacizumab), for the first-line treatment of unresectable or metastatic HCC.
Besides EMA’s orphan drug tag, amezalpat received the FDA’s ODD and Fast Track designation for treating HCC earlier this year.
All these designations were based on positive data from the phase Ib/II study, which evaluated amezalpat in combination with RHHBY’s standard-of-care combination therapy, Tecentriq and Avastin, for the first-line treatment of unresectable or metastatic HCC.
Data from the phase Ib/II study have shown that amezalpat, in combination with RHHBY’s standard-of-care combination therapy, Tecentriq and Avastin, demonstrated superior outcomes across multiple study endpoints, including overall survival, compared to the standard of care alone.
Year to date, shares of Tempest have plunged 26.8% against the industry’s rise of 10.4%.
Image Source: Zacks Investment Research
TPST Developing Another Candidate TPST-1495
The company is developing TPST-1495, a novel, highly selective and potent EP2-EP4 dual antagonist, for the treatment of familial adenomatous polyposis (FAP).
Tempest has also received a “Study May Proceed” letter from the FDA to begin a phase II study on TPST-1495 for the treatment of FAP. The study is expected to begin later in 2025, with data from the same expected in 2026.
The FDA has also granted an Orphan Drug designation to TPST-1495 for the treatment of patients with FAP.
Tempest is currently exploring strategic options to advance the clinical studies on its pipeline candidates aimed at increasing stockholder value.
TPST's Zacks Rank & Other Stocks to Consider
Tempest currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Lexicon Pharmaceuticals (LXRX - Free Report) and Chemomab Therapeutics (CMMB - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Lexicon’s loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents. Year to date, shares of LXRX have lost 2.9%.
LXRX’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%.
In the past 60 days, estimates for Chemomab Therapeutics’ loss per share have narrowed from 70 cents to 60 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 80 cents to 70 cents. Year to date, shares of CMMB have declined 27.9%.
CMMB’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 5.00%.